HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy

Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration–time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia. The target AUC for two patients who had already received...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2017-05, Vol.105 (5), p.686-691
Main Authors: Takagi, Masatoshi, Ishiwata, Yasuyoshi, Aoki, Yuki, Miyamoto, Satoshi, Hoshino, Akihiro, Matsumoto, Kazuaki, Nishimura, Akira, Tanaka, Mari, Yanagimachi, Masakatsu, Mitsuiki, Noriko, Imai, Kohsuke, Kanegane, Hirokazu, Kajiwara, Michiko, Takikawa, Kanako, Mae, Tsukasa, Tomita, Osamu, Fujimura, Junya, Yasuhara, Masato, Tomizawa, Daisuke, Mizutani, Shuki, Morio, Tomohiro
Format: Article
Language:English
Subjects:
Adenine Nucleotides - administration & dosage
Arabinonucleosides - administration & dosage
Busulfan - administration & dosage
Child
Female
Follow-Up Studies
Haploidy
Hematology
Hematopoietic Stem Cell Transplantation
HLA Antigens - genetics
Humans
Leukemia - therapy
Male
Medicine
Medicine & Public Health
Oncology
Original Article
Recurrence
Remission Induction
Time Factors
Transplantation Conditioning
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration–time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia. The target AUC for two patients who had already received multiple transplantations was 3600 and 4000 μmol min/L, and that for the patient with Down’s syndrome was 3000 μmol min/L. Regimen-related toxicity was well tolerated in all cases. All three maintained cytological remission throughout the follow-up period (between 31 and 167 weeks). Thus, haploidentical HCT conditioning with clofarabine and target AUC-based busulfan adjustment may be a preferable option for children with recurrent or refractory pediatric leukemia.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-017-2187-3